Clinical Trial Update: Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating response of acromegaly cardiomyopathy to cyclic GMP PDE5 inhibitors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly Cardiomyopathy

Snippet

Sponsor: Andrea M. Isidori | Conditions: Acromegaly Cardiomyopathy | Phase 2 | Status: COMPLETED